WaveMan
WaveMan · Company
SGHT · Sight Sciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SGHT Sight Sciences (SGHT) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001531177
Quote by TradingView
Form 144 · 14
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
61
13F, latest reported quarter

What the filings say about SGHT

Insiders, 180 days
-$1.1M net sold
1 buyer · 6 sellers · 42% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.9M
14 notices

Sight Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Sight Sciences, Inc. insiders sold a net $1.1M of stock across 133 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bauerlein Alison
Chief Operating Officer
SELL
2026-10-05 SECtraded 2026-10-02
25,260
$223.6K
+5.4%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jul 2, 2026.
  • The trade is 4.0% of the 639,449 shares held after it.
  • 4 other insiders sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Bauerlein Alison sold about $223.6K of SGHT under a 10b5-1 plan on Oct 2, 2026; 4 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.
Rodberg James
Chief Financial Officer
SELL
2026-10-05 SECtraded 2026-10-02
7,208
$63.8K
+5.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 2, 2026.
  • The trade is 3.3% of the 216,829 shares held after it.
  • 4 other insiders sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Rodberg James sold about $63.8K of SGHT under a 10b5-1 plan on Oct 2, 2026; 4 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.
Taylor Brenton
EVP, Operations & R&D
SELL
2026-10-05 SECtraded 2026-10-02
2,988
$26.5K
+5.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jul 1, 2026.
  • The trade is 1.1% of the 261,990 shares held after it.
  • 4 other insiders sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Operations & R&D Taylor Brenton sold about $26.5K of SGHT under a 10b5-1 plan on Oct 2, 2026; 4 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.
Badawi Paul
President and CEO
SELL
2026-10-05 SECtraded 2026-10-01
29,653
$268.3K
+5.4%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jul 1, 2026.
  • The trade is 0.5% of the 6,092,819 shares held after it.
  • 4 other insiders sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Badawi Paul sold about $268.3K of SGHT under a 10b5-1 plan on Oct 1, 2026; 4 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.
Badawi David
Chief Technology Officer
SELL
2026-10-05 SECtraded 2026-10-01
7,797
$70.6K
+5.4%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jul 6, 2026.
  • The trade is 0.4% of the 1,975,075 shares held after it.
  • 4 other insiders sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Badawi David sold about $70.6K of SGHT under a 10b5-1 plan on Oct 1, 2026; 4 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.
133 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 128 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.1M over 180 days
-$652.8K over 90 days · -$355.0K of it by a 10%+ holder
below 62% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
61 funds bought in last quarter
more than 50% of Medical Devices
Revenue
-3.1% year over year
below 81% of Medical Devices
Margin
-49.7% net margin
below 68% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.0% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
below 62% of Medical Devices
What changed in the last 30 days
Oct 5President and CEO Badawi Paul sold $268.3K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Chief Operating Officer Bauerlein Alison sold $223.6K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Officer Bauerlein Alison filed to sell $223.6K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer Badawi Paul filed to sell $268.3K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 30Former Officer HAYDEN JEREMY B. filed to sell $208.1K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch SGHT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+73.1%12M
-34%+4%+42%+80%2025-102025-122026-022026-042026-062026-082026-10 2025-11-25 · HAYDEN JEREMY B. sold $362.4K2026-10-01 · Badawi Paul sold $268.3K2026-10-02 · Bauerlein Alison sold $223.6K2026-01-02 · Badawi Paul sold $188.4K2026-07-01 · Badawi Paul sold $155.5K2026-01-16 · Badawi Paul sold $148.0K2026-07-02 · Bauerlein Alison sold $129.6K2025-12-16 · Encrantz Staffan bought $116.0K2026-04-01 · Badawi Paul sold $108.2K2025-11-17 · Taylor Brenton sold $101.8K2026-04-02 · Bauerlein Alison sold $90.0K2026-01-06 · Badawi Paul sold $88.8K2026-01-05 · Bauerlein Alison sold $85.2K2026-01-05 · HAYDEN JEREMY B. sold $73.4K2026-01-06 · Bauerlein Alison sold $72.2K2026-10-01 · Badawi David sold $70.6K2026-07-06 · HAYDEN JEREMY B. sold $70.1K2026-06-10 · Encrantz Staffan bought $68.8K2026-05-18 · Bauerlein Alison sold $65.2K2026-10-02 · Rodberg James sold $63.8K2026-04-06 · HAYDEN JEREMY B. sold $48.9K2026-01-16 · HAYDEN JEREMY B. sold $41.8K2026-07-06 · Badawi David sold $40.9K2026-07-02 · Rodberg James sold $37.0K2026-01-05 · Rodberg James sold $34.4K2026-01-16 · Badawi David sold $32.0K2026-04-02 · Badawi David sold $28.4K2026-01-06 · Badawi David sold $27.6K2026-10-02 · Taylor Brenton sold $26.5K2026-04-06 · Rodberg James sold $25.7K2025-11-12 · HAYDEN JEREMY B. sold $25.2K2026-01-05 · Badawi David sold $23.9K2026-01-02 · Badawi David sold $21.7K2025-12-02 · Rodberg James sold $20.8K2026-01-16 · Rodberg James sold $17.3K2026-07-01 · Taylor Brenton sold $15.3K2026-01-06 · HAYDEN JEREMY B. sold $13.4K2026-04-01 · Taylor Brenton sold $10.6K2026-01-06 · Taylor Brenton sold $4.6K2026-01-06 · Rodberg James sold $4.4K2026-10-02 · Bauerlein Alison filed to sell $223.6K2026-10-02 · Rodberg James filed to sell $63.8K2026-10-02 · Taylor Brenton filed to sell $26.5K2026-10-01 · Badawi David filed to sell $70.6K2026-10-01 · Badawi Paul filed to sell $268.3K2026-10-01 · HAYDEN JEREMY B. filed to sell $24.8K2026-09-30 · HAYDEN JEREMY B. filed to sell $208.1K2026-09-04 · HAYDEN JEREMY B. filed to sell $101.3K2026-09-01 · HAYDEN JEREMY B. filed to sell $110.0K2026-08-17 · HAYDEN JEREMY B. filed to sell $97.8K2026-08-14 · HAYDEN JEREMY B. filed to sell $395.9K2026-08-13 · HAYDEN JEREMY B. filed to sell $20.8K2026-08-12 · HAYDEN JEREMY B. filed to sell $133.3K2026-08-11 · HAYDEN JEREMY B. filed to sell $165.9K2026-07-06 · Badawi David filed to sell $40.9K2026-07-06 · HAYDEN JEREMY B. filed to sell $70.1K2026-07-02 · Bauerlein Alison filed to sell $129.5K2026-07-02 · Rodberg James filed to sell $37.0K2026-07-01 · Badawi Paul filed to sell $155.4K2026-07-01 · Taylor Brenton filed to sell $15.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SGHT: institutional holders (13F)

13F holdings, latest reported quarter
Long Focus Capital Management, LLC
3,844,100 sh
$20.8M
BlackRock, Inc.
3,083,108 sh
$16.7M
Americana Partners, LLC
1,679,069 sh
$9.1M
Pathstone Holdings, LLC
1,678,980 sh
$9.1M
VANGUARD CAPITAL MANAGEMENT LLC
1,573,815 sh
$8.5M

Congress trades in SGHT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SGHT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Bauerlein Alison
Filed 2026-10-02
$223.6K
Rodberg James
Filed 2026-10-02
$63.8K
Taylor Brenton
Filed 2026-10-02
$26.5K
Badawi David
Filed 2026-10-01
$70.6K
Badawi Paul
Filed 2026-10-01
$268.3K

SGHT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$301.0K position · as of 2026-06-30
0.2%
Zacks Small-Cap Core Fund
$34.4K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$717.2K position · as of 2026-06-30
0.0%
Gabelli Global Mini Mites Fund
$12.5K position · as of 2026-06-30
0.0%
AVIP BlackRock Advantage Small Cap Growth Portfolio
$59.1K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$100.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 4
0 active
14
Not applicable
2 active
What changed recently
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma
2026-10-20 · Completion moved 2026-08-31 → 2026-12-01
Not applicable
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma
2026-10-20 · Recruiting → Active Not Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.1M sold by insiders over 180 days, 61 funds added last quarter, $1.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

SGHT financials

Revenue growth
-3.1%
XBRL, annual
Net margin
-49.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$83.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-35.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$23.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.77x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.57x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-48.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-26.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-28.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$457.9M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-4.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$77.4M$79.9M$81.1M$71.3M
Gross profit$66.7M$68.3M$69.2M$59.0M
Operating income-$37.1M-$50.5M-$57.3M-$84.0M
Net income-$38.4M-$51.5M-$55.5M-$86.2M
EPS (diluted)-0.74-1.03-1.14-1.80
Operating cash flow-$29.7M-$22.4M-$47.2M-$76.0M
Cash$92.0M$120.4M$138.1M$185.0M
Long-term debt$40.3M$39.4M$31.7M$33.3M
SEC XBRL, fiscal years, as known on 2026-10-28

SGHT Stock Sonar score 6/7 axes

Find similar shapesCompare

SGHT ranks highest on risk and compliance (65th percentile) and insider conviction (47th), and lowest on growth (19th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
40
Inputs
  • Return on equity-48.4% · 38 pct, sector of 183
  • Return on assets-26.2% · 42 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-28.7% · 42 pct, sector of 188
Financial health
33
Inputs
  • Debt to equity0.77x · 25 pct, sector of 159
  • Cash flow to debt-0.57x · 42 pct, sector of 150
Growth
19
Inputs
  • Revenue growth, YoY-3.1% · 19 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
47
Inputs
  • Net Form 4 buying (codes P and S), 180d-$445K · 42 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
43
Inputs
  • Funds adding, latest quarter61 · 50 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$160K · 37 pct, sector of 50
Risk and compliance
65
Inputs
  • Short interest, % of float+4.0% · 55 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.5% · 40 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SGHT filings, in plain words

Are Sight Sciences insiders buying or selling SGHT?

In the 180 days to 2026-10-28, Sight Sciences insiders were net sellers, a net $1.1M: $68.8K of purchases and $1.2M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of SGHT?

Yes. 14 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.9M of stock; the latest, by Bauerlein Alison, was filed 2026-10-02.

Read the full summary

In the 180 days to 2026-10-28, Sight Sciences insiders were net sellers of SGHT, a net $1.1M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 42% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 14 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies